Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial

被引：0
|
作者：
Fizazi, K. [1 ]
Mella, P. Gonzalez
Castellano, D.
Minatta, J. N.
Kalebasty, A. R.
Shaffer, D.
Limon, J. C. Vazquez
Lopez, H. M. Sanchez
Armstrong, A. J.
Horvath, L.
Bastos, D. A.
Amin, N. P.
Li, J.
Unsal-Kacmaz, K.
Retz, M.
Saad, F.
Petrylak, D. P.
Pachynski, R. K.
机构：
[1] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷 / 02期
关键词：
D O I：
10.1097/JU.0000000000003046
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：445 / 446
页数：2
相关论文
共 50 条
  • [41] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Tagawa, Scott T.
    Ramaswamy, Krishnan
    Huang, Ahong
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Sandin, Rickard
    Lechpammer, Stanislav
    George, Daniel J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1032 - 1040
  • [42] Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naive metastatic castration-resistant prostate cancer in Japan
    Okumura, Hiroyuki
    Inoue, Sachie
    Naidoo, Shevani
    Holmstrom, Stefan
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (08) : 1319 - 1329
  • [43] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [44] Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
    Heath, Elisabeth
    Heilbrun, Lance
    Mannuel, Heather
    Liu, Glenn
    Lara, Primo
    Monk, J. Paul
    Flaig, Thomas
    Zurita, Amado
    Mack, Philip
    Vaishampayan, Ulka
    Stella, Philip
    Smith, Daryn
    Bolton, Susan
    Hussain, Arif
    Al-Janadi, Anas
    Silbiger, Daniel
    Usman, Muhammad
    Ivy, S. Percy
    ONCOLOGIST, 2019, 24 (09): : 1149 - +
  • [45] A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
    Twardowski, Przemyslaw W.
    Beumer, Jan H.
    Chen, C. S.
    Kraft, Andrew S.
    Chatta, Gurkamal S.
    Mitsuhashi, Masato
    Ye, Wei
    Christner, Susan M.
    Lilly, Michael B.
    ANTI-CANCER DRUGS, 2013, 24 (07) : 743 - 753
  • [46] Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).
    Sartor, A. Oliver
    Oudard, Stephane
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjoern
    Hjelm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel E.
    Mainwaring, Paul N.
    Bernard, John P.
    Shen, Liji
    Chadjaa, Mustapha
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1032 - 1040
  • [48] Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Carlo Buonerba
    Piera Federico
    Carmine D’Aniello
    Pasquale Rescigno
    Carla Cavaliere
    Livio Puglia
    Matteo Ferro
    Vincenzo Altieri
    Sisto Perdonà
    Sabino De Placido
    Giuseppe Di Lorenzo
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1455 - 1461
  • [49] Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09)
    Rothermundt, Christian
    Hayoz, Stefanie
    Templeton, Arnoud J.
    Winterhalder, Ralph
    Strebel, Raeto T.
    Baertschi, Daniela
    Pollak, Michael
    Lui, Lillianne
    Endt, Kathrin
    Schiess, Ralph
    Rueschoff, Jan H.
    Cathomas, Richard
    Gillessen, Silke
    EUROPEAN UROLOGY, 2014, 66 (03) : 468 - 474
  • [50] Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction
    Cindolo, Luca
    Natoli, Clara
    De Nunzio, Cosimo
    De Tursi, Michele
    Valeriani, Maurizio
    Giacinti, Silvana
    Micali, Salvatore
    Rizzo, Mino
    Bianchi, Giampaolo
    Martorana, Eugenio
    Scarcia, Marcello
    Ludovico, Giuseppe Mario
    Bove, Pierluigi
    Laudisi, Anastasia
    Selvaggio, Oscar
    Carrieri, Giuseppe
    Bada, Maida
    Castellan, Pietro
    Topazio, Luca
    Boccasile, Stefano
    Ditonno, Pasquale
    Chiodini, Paolo
    Schips, Luigi
    CLINICAL GENITOURINARY CANCER, 2017, 15 (05) : 520 - 525
12345